Promaxo
Promaxo develops a portable low-field MRI platform with AI lesion localization and robotic needle guidance for point-of-care prostate biopsy in urology practices, ambulatory surgery centers, and hospitals.
- Company typePrivate
- Founded2016
- HeadquartersOakland, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Promaxo does
Promaxo Holdings, Inc. is a privately held medical imaging, robotics, and AI company founded in 2016 and headquartered in Oakland, California. The company develops and commercializes a portable low-field MRI platform designed for point-of-care use in urology practices and ambulatory surgery centers, with FDA 510(k) clearance (K230123) for MRI-guided prostate biopsy — the first such clearance in the United States for a portable low-field MRI in this indication. The core technology combines a miniaturized MRI scanner using a patented pseudo-birdcage coil architecture with complementary AI-driven lesion localization and robotic needle guidance modules (the latter two are not yet FDA cleared for commercial use). The platform is intended to allow urologists to perform MRI-guided prostate biopsies in-office, eliminating the need to refer patients to external imaging centers.
The company's product portfolio consists of the Promaxo MRI System (core, FDA-cleared), MRI-Guided Biopsy procedures, AI-Driven Insights (lesion localization/targeting optimization, pending FDA clearance), Robotics (live MR-guided needle guidance, pending FDA clearance), and MRI-Targeted Treatment (therapeutic intervention add-on). Revenue mechanics are anchored on direct enterprise sales of MRI hardware to urology practices, ASCs, and hospital systems, supplemented by recurring service and support contracts; pricing is quote-based and not publicly disclosed. Go-to-market relies on enterprise field sales, demo scheduling, conference presence (e.g., AUA 2026), and a multi-channel digital presence (LinkedIn, YouTube, X, Facebook).
The company has raised approximately $129M+ across multiple funding rounds spanning 2017 through 2026, including 2024 and 2026 Form D exempt offerings with participation from over 100 investors. Strategic backers include Zynext Ventures (Zydus Lifesciences VC arm), Spark Growth Ventures, MicroPort Scientific, Kineticos Life Sciences, and surgical robotics pioneer Fred Moll, who serves as a strategic advisor. The company operates exclusively in the United States and has 51-100 employees.
Promaxo firmographics
Firmographics- Name
- Promaxo
- Legal name
- Promaxo Holdings, Inc.
- Website
- https://promaxo.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Promaxo develops a portable low-field MRI platform with AI lesion localization and robotic needle guidance for point-of-care prostate biopsy in urology practices, ambulatory surgery centers, and hospitals.
- Ownership category
- akta.pro rank
Promaxo industry classification
Industry- Product category
- Medical Imaging Equipment
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
- akta.pro secondary industry
- Medical Imaging AI (HDAAAEAH)
Keywords
Where Promaxo is headquartered
LocationHeadquarters
- HQ city
- Oakland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Promaxo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- MRI Hardware Sales: Sale of the Promaxo MRI System, a portable low-field MRI device for point-of-care prostate biopsy procedures. The FDA 510(k) cleared system is sold directly to urology practices, ASCs, and hospitals.
- Service and Support: Ongoing service, maintenance, and support for installed MRI systems, likely representing recurring revenue from existing customer base.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Promaxo product offering
Product offeringCore offering
Promaxo develops and sells a portable, low-field point-of-care MRI system (FDA 510(k) cleared, K230123) for MRI-guided prostate biopsy in urology practices, ambulatory surgery centers, and hospitals. The platform combines the MRI scanner with AI-driven lesion localization and robotic needle guidance under live MR imaging to enable targeted prostate biopsy and treatment without referring patients to dedicated imaging centers.
Product overview
Promaxo offers a point-of-care MR guidance platform for prostate biopsy, integrating MRI imaging, AI-driven analytics, and robotics into a unified system. The core offering is the Promaxo MRI System (FDA 510(k) cleared), supplemented by the MRI-Guided Biopsy module for procedural guidance, AI-Driven Insights for lesion localization and targeting optimization, Robotics for precision needle guidance, and MRI-Targeted Treatment for point-of-care interventions. The platform is designed for urologists and can be installed at ambulatory surgery centers (ASCs) and hospitals.
Differentiator
Problem solved
Functional benefit
Products and services
- Promaxo MRI System Portable, low-field point-of-care MRI system FDA 510(k) cleared (K230123) for MRI-guided prostate biopsy. Sold to urology practices, ambulatory surgery centers, and hospitals.
- MRI-Guided Biopsy Procedure offering for guided prostate biopsies performed at the point of care using real-time MRI imaging for precise needle placement and tissue sampling. For urologists and ASCs.
- MRI-Targeted Treatment Targeted treatment capability delivered at the point of care using MRI-guided interventions for prostate care. For urology practices and hospitals.
Quantifiable outcome
- First in US FDA clearance for prostate biopsy and treatment using portable MRI
- +1 more outcomes
Companies that use Promaxo
Customer profileSegments3 records
Ideal customer profiles3 records
Promaxo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Promaxo partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights7 records
Promaxo competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Promaxo social profiles
Digital presencePromaxo compliance and trust
Trust signalCompliance1 record
Promaxo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Promaxo leadership team
Management profileNumber of profiles
Profiles6 records
Promaxo funding detail
Funding detailFunding overview
Funding rounds9 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Promaxo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Promaxo
What does Promaxo do?
Promaxo develops and sells a portable, low-field point-of-care MRI system (FDA 510(k) cleared, K230123) for MRI-guided prostate biopsy in urology practices, ambulatory surgery centers, and hospitals. The platform combines the MRI scanner with AI-driven lesion localization and robotic needle guidance under live MR imaging to enable targeted prostate biopsy and treatment without referring patients to dedicated imaging centers.
Is Promaxo a public or private company?
Promaxo is a private company. It is classified as venture growth investor backed and is currently operating.
When was Promaxo founded?
Promaxo was founded in 2016. It employs 51 to 100 people.
Where is Promaxo based?
Promaxo is headquartered in Oakland, United States, in the North America region.
How does Promaxo make money?
Two revenue lines are on record. MRI Hardware Sales are the primary driver. The others are service and Support.
Does Promaxo have an API?
No public API is recorded for Promaxo.
What industry is Promaxo in?
Promaxo's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.